NEWS
OUR DEALS IN THE NEWS
Transaction Advisor to Allecra Therapeutics GmbH
June 24, 2024 – STAATZ Business Development & Strategy acted as strategic and operational business development advisor to the German/French biopharmaceutical company Allecra Therapeutics to secure an exclusive License and Supply Agreement with Acino International AG for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa. EXBLIFEP® has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of severe infections earlier in 2024.
Transaction Advisor to Lallemand Pharma
Transaction Advisor to Retinagix Holdings, LLC
January 19, 2022 – STAATZ Business Development & Strategy acted as strategic and operational business development advisor to the US biopharmaceutical company Retinagix Holdings to secure an asset acquisition agreement for Oral 9-cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness with Eluminex Biosciences (Suzhou) Limited (China). In return for the global rights to the clinical stage asset Retinagenix is entitled to an upfront payment and earnout payments related to the achievement of certain clinical, regulatory, and commercial milestones as well as to payments based upon worldwide net sales of products and the sale or use of priority review vouchers.
Transaction Advisor to Allecra Therapeutics GmbH
January 13, 2022 – STAATZ Business Development & Strategy acted as strategic and operational business development advisor to the German/French biopharmaceutical company Allecra Therapeutics to secure an exclusive License and Supply Agreement for Europe with Advanz Pharma. In return for exclusive commercial rights for the European Union, the United Kingdom, Switzerland, and Norway for the post phase III proprietary antibiotic combination product cefepime/enmetazobactam Allecra is entitled to upfront, development and commercial milestone payments, in addition to double-digit royalties.
Transaction Advisor to GamaMabs Pharma SA
May 04, 2021 – STAATZ Business Development & Strategy acted as strategic and operational business development advisor to the French immuno-oncology company GamaMabs to secure an Asset Purchase Agreement with Exelixis, Inc for GamaMabs’ first-in-class humanized antibody program against anti-Müllerian hormone receptor 2 (AMHR2), a novel oncology target.
Exelixis will apply their ADC capabilities to GamaMabs’ panel of antibodies against AMHR2 to develop new therapeutics against various tumors. In return for all rights, title and interest to the AMHR2 technology including the rights pertaining to GamaMabs’ clinical stage monoclonal antibody drug murlentamab, GamaMabs is entitled to payments upon signature as well as closing and to further payments contingent upon various events.
Transaction Advisor to Allecra Therapeutics GmbH
December 21, 2020 – STAATZ Business Development & Strategy acted as strategic and operational business development advisor to the German/French biopharmaceutical company Allecra Therapeutics to secure an exclusive License Agreement for Greater China with Shanghai Haini Pharmaceutical Co., Ltd., the subsidiary of Yangtze River Pharmaceutical. In return for exclusive manufacturing, development and commercial rights in the territory for the post phase III proprietary antibiotic combination product cefepime/enmetazobactam which was shown to overcome antibiotic resistance in indications such as complicated urinary tract infections Allecra is entitled to upfront, milestone payments and royalties on net sales at an overall deal value of up to US$78mill.
http://allecra.com/images/images/2020pdf/20201221_Haini_Allecra_PR_Final.pdf
Transaction Advisor to German Cancer Research Center (DKFZ)
September 14, 2020 – Staatz Business Development & Strategy acted as strategic and operational business development advisor to the German Cancer Research Center (DKFZ) and the University of Tuebingen in the creation of the new company Cullinan Florentine. Staatz BD&D supported Cullinan Florentine also in securing the exclusive, wordwide license to CLN-049, a novel bispecific antibody for AML that the new company took from DKFZ and University of Tuebingen.
Transaction Advisor to Sapiotec GmbH
January 20, 2020 – Staatz Business Development & Strategy acted as transaction advisor to Sapiotec GmbH, a pharmaceutical development company spin-off from the University clinic Würzburg, regarding a development, licensing, and patent acquisition contract with a Germany-based global intensive care company, to develop a novel pharmaceutical product for anaesthesia.
German Cancer Research Center (DKFZ)
December 20, 2019 – Staatz Business Development & Strategy acted as strategic and operational business development advisor to the German Cancer Research Center (DKFZ) and the University of Tuebingen regarding a license and cooperation agreement with the South Korean biotech company ABL Bio on two substances of clinical quality for cancer. Press release: https://www.dkfz.de/en/presse/pressemitteilungen/2019/dkfz-pm-19-59-DKFZ-and-DKTK-scientists-granted-patent-for-innovative-antibody-design.php
Horama S.A
December 9, 2019 – Staatz Business Development & Strategy acted as strategic and operational business development advisor to the Paris-based ophthalmic gene-therapy specialist company Horama S.A., in securing a master research agreement and an in- licensing agreement from a European based academic centre for an innovative gene therapy product for retinitis pigmentosa and other rare ophthalmology diseases.
Talix Therapeutics N.V.
November 18, 2019 – Staatz Business Development & Strategy acted as strategic and operational business development advisor to the Belgian/French biotechnology company Talix Therapeutics N.V. regarding an MTA and exclusive option to a license agreement with the USA based subsidiary of a Japanese multinational pharmaceutical company. Upon availability of certain results the partner will have the right to exercise the exclusive option to a global, exclusive license agreement for a novel monoclonal antibody in development for tumor indication.
July 12, 2019 – STAATZ BD&S acted as strategic and operational business development advisor to BliNK Biomedical during the negotiation of a Commercial License Agreement with Genmab A/S. Genmab will use their DuoBody technology and a CD47 antibody from BliNK Biomedical to develop the CD47 target with a bispecific approach. BliNK Biomedical will receive an upfront payments of USD 2.25 million and is eligible to receive up to approximately USD 200 million in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales.
Press release:
https://ir.genmab.com/news-releases/news-release-details/genmab-and-blink-biomedical-enter-commercial-license-agreement
German Cancer Research Center (DKFZ)
June 6, 2019 – Staatz Business Development & Strategy acted as strategic and operational business development advisor to the German Cancer Research Center (DKFZ) and the University of Tuebingen with a Delaware based corporation regarding an exclusive option to an exclusive, worldwide license agreement for a proprietary product candidate for cancer.
Privately-held French Biotechnology Client
June 4, 2018 ─ Staatz acted as strategic and operational business development advisor to a privately held French biotechnology client for a contract with a private US biotechnology company regarding an asset purchase agreement for a family of proprietary pre-clinical stage antibodies which are designed for application in various tumor and other indication areas.
French Biotechnology Client
June 1, 2018 ─ Staatz acted as strategic and operational business development advisor to a French biotechnology client for a contract with a mid-size public European biotechnology company regarding a global, exclusive research collaboration and commercial license option agreement on bispecific antibodies for tumor indications.
October 10, 2017 ─ Staatz Business Development & Strategy acted as transaction advisor to GamaMabs Pharma, a France-based immuno-oncology biotechnology Company, in a licensing agreement with Medimmune, the global biologics research and development arm of AstraZeneca, to develop an antibody drug conjugate (ADC) to treat cancer:
MedImmune and GamaMabs Enter Licensing Agreement to Develop Antibody Drug Conjugate Targeting Cancer
May 8, 2017 ─ Staatz acted as business development advisor to Luxendo, a spin-off of the European Molecular Biology Laboratory (EMBL), regarding its all share sale to Bruker Corp., USA:
EMBL Ventures portfolio company Luxendo acquired by Bruker: successful exit…
March 31, 2017 ─ Our team advised Swiss-based Calypso Biotech in its global licensing and collaboration agreement with EA Pharma, Japan.
March 16, 2017 ─ Staatz acted as strategic and operational business development advisor to its US biotechnology client regarding a research collaboration and option agreement with a US-based mid-size biotechnology company for a global, exclusive license on a targeted CAR cell therapy product.
